Proapoptotic therapy with oblimersen (bcl-2 antisense oligonucleotide) - Review of preclinical and clinical results;Proapoptotische therapie mit oblimersen (bcl-2-antisense-oligonukleotid) - Übersicht über präklinische und klinische daten

Onkologie

Volumn 26, Issue SUPPL. 7, 2003, Pages 60-69

  Buchele T ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Antisense oligonucleotide; Bcl 2; Cancer therapy; Combination therapy; Oblimersen

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MESSENGER RNA; MONOCLONAL ANTIBODY; OBLIMERSEN; PREDNISOLONE; PROTEIN BCL 2; RIBONUCLEASE H; RITUXIMAB; THALIDOMIDE; VINCRISTINE; NUCLEOTIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CODON; COLORECTAL CARCINOMA; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; FOLLICULAR LYMPHOMA; HUMAN; MELANOMA; MITOCHONDRION; MOLECULAR DYNAMICS; MULTIPLE MYELOMA; NASOPHARYNX CARCINOMA; NONHUMAN; PROSTATE CARCINOMA; REVIEW; RNA DEGRADATION; SOLID TUMOR; TOXICITY; ANIMAL; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; FEMALE; GENETICS; MALE; NEOPLASM; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; APOPTOSIS; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; MALE; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; THIONUCLEOTIDES; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 9144268607     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076177     Document Type: Review

References (61)

1. Reed JC: Dysregulation of apoptosis in cancer. J Clin Oncol 1999;17:2941-2953.
2. Nicholson DW: From bench to clinic with apoptosis-based therapeutic agents. Nature 2000;407:810-816.
3. Korsmeyer SJ: BCL-2 gene family and the regulation of programmed cell death. Cancer Res 1999; 59:1693s-1700s.
4. Reed JC: Mechanisms of apoptosis. Am J Pathol 2000;157:1415-1430.
5. Reed JC, Kitada S, Takayama S, Miyashita T: Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol 1994;5(suppl 1):61-65.
6. Schmitt CA, Rosenthal CT, Lowe SW: Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med 2000;6:1029-1035.
7. Maung ZT, MacLean FR, Reid MM, Pearson AD, Proctor SJ, Hamilton PJ, Hall AG: The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia. Br J Haematol 1994;88:105-109.
8. Bhargava V, Kell DL, van de RM, Warnke RA: Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 1994;145:535-540.
9. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F, Veronesi U: The Bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994; 86:499-504.
10. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL: bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 1994;69:135-139.
11. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B: bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995;55:237-241.
12. Ikegaki N, Katsumata M, Minna J, Tsujimoto Y: Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 1994;54:6-8.
13. Jiang SX, Sato Y, Kuwao S, Kameya T: Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol 1995;177:135-138.
14. Gaulard P, d'Agay MF, Peuchmaur M, Brousse N, Gisselbrecht C, Solal-Celigny P, Diebold J, Mason DY: Expression of the bcl-2 gene product in follicular lymphoma. Am J Pathol 1992;140:1089-1095.
15. Pezzella F, Ralfkiaer E, Gatter KC, Mason DY: The 14;18 translocation in European cases of follicular lymphoma: Comparison of Southern blotting and the polymerase chain reaction. Br J Haematol 1990;76:58-64.
16. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52: 6940-6944.
17. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R: Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol 1993;143:390-400.
18. Lu QL, Elia G, Lucas S, Thomas JA: Bcl-2 protooncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma. Int J Cancer 1993; 53:29-35.
19. Kamada S, Shimono A, Shinto Y, Tsujimura T, Takahashi T, Noda T, Kitamura Y, Kondoh H, Tsujimoto Y: bcl-2 deficiency in mice leads to pleiotropic abnormalities: Accelerated lymphoid cell death in thymus and spleen, polycystic kidney, hair hypopigmentation, and distorted small intestine. Cancer Res 1995;55:354-359.
20. Nakayama K, Nakayama K, Negishi I, Kuida K, Sawa H, Loh DY: Targeted disruption of Bcl-2 alpha beta in mice: Occurrence of gray hair, polycystic kidney disease, and lymphocytopenia. Proc Natl Acad Sci U S A 1994;91:3700-3704.
21. Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ: Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 1993;75:229-240.
22. Yamamura K, Kamada S, Ito S, Nakagawa K, Ichihashi M, Tsujimoto Y: Accelerated disappearance of melanocytes in bcl-2-deficient mice. Cancer Res 1996;56:3546-3550.
23. McDonnell TJ and Korsmeyer SJ: Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature 1991;20001218:254-256.
24. Wintersberger U: Ribonucleases H of retroviral and cellular origin. Pharmacol Ther 1990;48:259-280.
25. Zamecnik PC and Stephenson ML: Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A 1978;75:280-284.
26. Ho SP, Britton DH, Stone BA, Behrens DL, Leffet LM, Hobbs FW, Miller JA, Trainor GL: Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries. Nucleic Acids Res 1996;24:1901-1907.
27. Ho SP, Bao Y, Lesher T, Malhotra R, Ma LY, Fluharty SJ, Sakai RR: Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nat Biotechnol 1998;16:59-63.
28. Agrawal S, Temsamani J, Tang JY: Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A 1991;88:7595-7599.
29. Raynaud FI, Orr RM, Goddard PM, Lacey HA, Lancashire H, Judson IR, Beck T, Bryan B, Cotter FE: Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther 1997;281:420-427.
30. Kuss B and Cotter F: Antisense - time to shoot the messenger. Ann Oncol 1999;10:495-503.
31. Gleave ME, Miayake H, Goldie J, Nelson C, Tolcher A: Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligo-deoxynucleotides. Urology 1999;54:36-46.
32. Guinness ME, Kenney JL, Reiss M, Lacy J: Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice. Cancer Res 2000;60:5354-5358.
33. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Muller M, Wolff K, Eichler HG, Pehamberger H: bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998;4:232-234.
34. Kitada S, Miyashita T, Tanaka S, Reed JC: Investigations of antisense oligonucleotides targeted against bcl-2 RNAs. Antisense Res Dev 1993;3: 157-169.
35. Klasa RJ, Bally MB, Ng R, Goldie JH, Gascoyne RD, Wong FM: Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res 2000;6:2492-2500.
36. Schlagbauer-Wadl H, Klosner G, Heere-Ress E, Waltering S, Moll I, Wolff K, Pehamberger H, Jansen B: Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice. J Invest Dermatol 2000;114:725-730.
37. Tolcher AW, Roth S, Wynne H, Quada J, Rowinsky EK, Thompson IM, Weitman S, Izbicka E: G3139 (Genasense) enhances docetaxel antitumor activity and leads to long-term survivors in the androgen-independent prostate cancer xenograph (PC3) model. Clin Cancer Res 2001;3680S
38. Yang D, Ling Y, Almazan M, Guo R, Murray A, Brown B, Lippman ME: Tumor regression of human breast carcinomas by combination therapy of anti-bcl-2 antisense oligonucleotide and chemotherapeutic drugs. Proc Am Assn Cancer Res 1999;40:729
39. Wacheck V, Krepler C, Strommer S, Heere-Ress E, Klem R, Pehamberger H, Eichler HG, Jansen B: Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice. Antisense Nucleic Acid Drug Dev 2002;12:359-367.
40. Waters J, Clarke P, Cunningham D, Miller D, Webb A, Corbo M, Cotter F: Bcl-2 antisense oligodeoxy-nucleotide (ODN)(G3139) therapy exerts its anti-tumor action through a sequence-specific antisense effect, and not a cell-mediated immune response. Proc Am Soc Clin Oncol 2000;19:14a
41. van de Donk NW, Kamphuis MM, Van Dijk M, Borst HP, Bloem AC, Lokhorst HM: Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein. Leukemia 2003;17:211-219.
42. Morris MJ, Tong WP, Cordon-Cardo C, Drobnjak M, Kelly WK, Slovin SF, Terry KL, Siedlecki K, Swanson P, Rafi M, DiPaola RS, Rosen N, Scher HI: Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2002;8:679-683.
43. de Bono J.S., Rowinsky E.K., Kuhn J., Basler J., Ochoa L., Schwartz G., Patnaik A., Hammond L.A., Smetzer L., Smith L., Fingert H., Weitman S.: Phase I pharmacokinetic (PK) and pharmacodynamic (PD) trial of bcl-2 antisense (Genasense) and docetaxel (D) in hormone refractory prostate cancer. Proc Am Soc Clin Oncol 2001;20:81.
44. Jansen B, Wacheck V, Heere-Ress E, Hoeller C, Lucas T, Pratscher B, Schaberl R, Eichler HG, Wolff K, Pehamberger H: Clinical, pharmacologic, and pharmacodynamic study of genasense (G3139, Bcl-2 antisense oligonucleotide) and dacarbazine (DTIC) in patients with malignant melanoma. Proc Am Soc Clin Oncol 2001;20:1426(abstr.)
45. Lacy J and Loomis R: Bcl-2 antisense (G3139, oblimersen) enhances the in vitro and in vivo response of EBV-associated lymphoproliferactive disease to rituximab. Proc Am Assn Cancer Res 2002;43:575.
46. Tauchi T, Nakajima A, Sumi M, Shimamoto T, Sashida G, Ohyashiki K: G3139 (Bcl-2 Antisense Oligonukleotide) Is Active Against Gleevec-Resistant Bcr-Abl-Positive Cells. Proc Am Assoc Cancer Res 2002;43:943-950.
47. Tortora G, Caputo R, Damiano V, Bianco R, Fontanini G, Cuccato S, De Placido S, Bianco AR, Ciardiello F: Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis. Clin Cancer Res 2001;7:2537-2544.
48. Vrignaud P, Lejeune P, Klem R, Bissery M-C: Combination Of G3139 (Genasense™), A Bcl-2 Anti-sense Oligonukleotide, With Docetaxel (Taxotere (R)) Is Active In A Murine Xenograft Model of Human Non-Small Cell Lung Cancer. Proc Am Assoc Cancer Res 2002;43:578.
49. Klasa RJ, List AF, Cheson BD: Rational approaches to design of therapeutics targeting molecular markers. Hematology (Am Soc Hematol Educ Program) 2001;443-462.
50. Lopes de Menezes DE, Hudon N, McIntosh N, Mayer LD: Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin Cancer Res 2000;6:2891-2902.
51. Wacheck V, Heere-Ress E, Halaschek-Wiener J, Lucas T, Meyer H, Eichler HG, Jansen B: Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model. J Mol Med 2001;79:587-593.
52. Klasa RJ, Gillum AM, Klem RE, Frankel SR: Oblimersen Bcl-2 antisense: Facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 2002;12:193-213.
53. Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, Di Stefano F, Cotter FE: Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2000;18:1812-1823.
54. Rai K and O'Brien S: Genasense (Bcl-2 Antisense) monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: Phase 1 and 2 results. Proc Annu Meet Am Soc Hematol 2002;100:384a.
55. Leonard JP, Coleman M, Vose J, et al: Phase II study of oblimersen sodium (G3139) alone and with R-CHOP in mantle cell lymphoma (MCL). Proc Am Soc Clin Oncol 2003;22:566.
56. Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C, Lucas T, Hoermann M, Hollenstein U, Wolff K, Pehamberger H: Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 2000;356:1728-1733.
57. Marcucci G, Byrd JC, Catalano SR, Fisher DB, Lucas D, Chen KK, Young D, Didier LA, Bloomfield CD, Balcerzak SP, Frankel SR, Kraut EH, Grever MR, Caligiuri MA: Significant disease response to GenasenseTM (G3139, Genta), a Bcl-2 antisense, in combination with chemotherapy in refractory or relapsed acute leukemia: A phase I study. American Academy Cancer Research-National Cancer Institite-European Organization for the Research and Treatment of Cancer International Conference 2001. Clin Cancer Res 2001:7(suppl): 3681(abstr 139).
58. Rudin C, Kosloff M, Edelmann MJ, Hoffmann PC, Szeto L, Vokes EE: Phase I study of G3139 (obliermsen sodium), carboplatin, and etoposide in previously untreated extensive stage small cell lung cancer (SCLC). [Abstract]. Proc Am Soc Clin Oncol 2003 2003;22:631.
59. Badros: IXth International Workshop on Multiple Myeloma, May 23-27, 2003, Salamanca, Spain.
60. Van de Donk N: IXth International Workshop on Multiple Myeloma, May 23-27, 2003, Salamanca, Spain.
61. Chi KN, Murray RN, Gleave ME, Kuhn J, Izbicka E, Berg K, Rowinsky EK, Tolcher AW: A phase II study of oblimersen sodium (G3139) and docetaxel (D) in patients (pts) with metastatic hormone-refractory prostate cancer (HRPC). [Abstract]. Proc Am Soc Clin Oncol 2003;22:393.